Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 109
Filter
3.
Osteoporos Int ; 31(1): 181-191, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31776637

ABSTRACT

Transitioning postmenopausal women with osteoporosis from a bisphosphonate to denosumab appears to be safe and more effective at improving BMD than continuing treatment with a bisphosphonate. INTRODUCTION: We conducted a patient-level pooled analysis of four studies to estimate the efficacy and safety of transitioning to denosumab vs. continuing bisphosphonate treatment in postmenopausal women who previously received oral bisphosphonates. METHODS: Patients received 60 mg denosumab once every 6 months or a bisphosphonate (oral alendronate, risedronate, ibandronate, or intravenous zoledronic acid). Endpoints were change from baseline in lumbar spine, total hip, femoral neck, and 1/3 radius BMD at month 12, change from baseline in serum CTX-1 and P1NP, and incidence of adverse events. RESULTS: A total of 2850 randomized patients (1424 bisphosphonate:1426 denosumab) were included in the analysis. Percentage change in BMD was significantly greater (p < 0.001) for denosumab vs. bisphosphonate at each skeletal site; differences in BMD changes ranged from 0.6 to 2.0%. Percentage decrease in serum CTX-1 and P1NP was significantly greater (p < 0.0001) for denosumab vs. bisphosphonate at months 1, 6, and 12; in the denosumab group only, percentage change in serum CTX-1 at month 1 was significantly correlated with percentage change in lumbar spine and total hip BMD at month 12. The incidences of adverse events were similar between treatment groups. Three patients (one bisphosphonate and two denosumab) had atypical femoral fractures, all from the denosumab vs. zoledronic acid study. CONCLUSION: Postmenopausal women can safely transition from a bisphosphonate to denosumab, which is more effective at improving BMD than continuing with a bisphosphonate. CLINICAL TRIALS REGISTRATION: NCT00377819, NCT00919711, NCT00936897, NCT01732770.


Subject(s)
Bone Density Conservation Agents , Denosumab , Diphosphonates , Osteoporosis, Postmenopausal , Aged , Bone Density , Bone Density Conservation Agents/adverse effects , Denosumab/adverse effects , Diphosphonates/adverse effects , Female , Humans , Middle Aged , Osteoporosis, Postmenopausal/drug therapy , Postmenopause
4.
Osteoporos Int ; 30(12): 2437-2448, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31628490

ABSTRACT

Romosozumab is a therapy that stimulates bone formation and reduces bone resorption. In this study of postmenopausal women with low BMD, a second course of romosozumab following a period off treatment or on denosumab increased or maintained BMD, respectively, and was well tolerated, providing insight into treatment sequence options. INTRODUCTION: In patients with high fracture risk, therapies that stimulate bone formation provide rapid BMD gains; currently available agents, parathyroid hormone receptor agonists, are limited to a 2-year lifetime exposure and generally used for a single treatment course. However, for long-term osteoporosis management, a second treatment course may be appropriate. Romosozumab, a therapy with the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months. Here, we report efficacy and safety of a second romosozumab course. METHODS: In this phase 2, dose-finding study, postmenopausal women with low bone mass (T-score ≤ - 2.0 and ≥ - 3.5) received romosozumab or placebo (month 0-24) followed by placebo or denosumab (month 24-36); participants then received a year of romosozumab (month 36-48). RESULTS: Of 167 participants who entered the month 36-48 period, 35 had been initially randomized to romosozumab 210 mg monthly. In participants who received romosozumab 210 mg monthly followed by placebo, a second romosozumab course (n = 19) increased BMD by amounts similar to their initial treatment (month 0-12) at the lumbar spine (12.4%; 12.0%, respectively) and total hip (6.0%; 5.5%, respectively). Following denosumab, a second romosozumab course (n = 16) increased BMD at the lumbar spine (2.3%) and maintained BMD at the total hip. Safety profiles were similar between first and second romosozumab courses. CONCLUSIONS: After 12 months off-treatment, a second romosozumab course again led to rapid and large BMD gains. Following denosumab, BMD gains with romosozumab were smaller than with initial treatment. No new safety findings were observed during the second course.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Denosumab/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Aged , Aged, 80 and over , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Biomarkers/blood , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/adverse effects , Bone Remodeling/drug effects , Denosumab/administration & dosage , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Drug Therapy, Combination , Female , Humans , Middle Aged , Osteoporosis, Postmenopausal/complications , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/etiology , Osteoporotic Fractures/prevention & control
5.
Osteoporos Int ; 30(1): 71-78, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30244369

ABSTRACT

This post-hoc analysis queried whether women experiencing fracture on denosumab indicates inadequate treatment response or whether the risk of subsequent fracture remains low with continuing denosumab. Results showed that denosumab decreases the risk of subsequent fracture and fracture sustained while on denosumab is not necessarily indicative of inadequate treatment response. INTRODUCTION: This analysis assessed whether a fracture sustained during denosumab therapy indicates inadequate treatment response and if the risk of a subsequent fracture decreases with continuing denosumab treatment. METHODS: In FREEDOM, a clinical trial to evaluate the efficacy and safety of denosumab, postmenopausal women with osteoporosis were randomized to placebo or denosumab for 3 years. In the 7-year FREEDOM Extension, all participants were allocated to receive denosumab. Here we compare subsequent osteoporotic fracture rates between denosumab-treated subjects during FREEDOM or the Extension and placebo-treated subjects in FREEDOM. RESULTS: During FREEDOM, 438 placebo- and 272 denosumab-treated subjects had an osteoporotic fracture. Exposure-adjusted subject incidence per 100 subject-years was lower for denosumab (6.7) vs placebo (10.1). Combining all subjects on denosumab from FREEDOM and the Extension for up to 10 years (combined denosumab), 794 (13.7%) had an osteoporotic fracture while on denosumab. Of these, one or more subsequent fractures occurred in 144 (18.1%) subjects, with an exposure-adjusted incidence of 5.8 per 100 subject-years, similar to FREEDOM denosumab (6.7 per 100 subject-years) and lower than FREEDOM placebo (10.1 per 100 subject-years). Adjusting for prior fracture, the risk of having a subsequent on-study osteoporotic fracture was lower in the combined denosumab group vs placebo (hazard ratio [95% CI]: 0.59 [0.43-0.81]; P = 0.0012). CONCLUSIONS: These data demonstrate that denosumab decreases the risk of subsequent fracture and a fracture sustained while on denosumab is not necessarily indicative of inadequate treatment response.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Denosumab/therapeutic use , Osteoporotic Fractures/prevention & control , Aged , Aged, 80 and over , Bone Density/drug effects , Double-Blind Method , Female , Follow-Up Studies , Humans , Middle Aged , Osteoporosis, Postmenopausal/complications , Osteoporosis, Postmenopausal/drug therapy , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/etiology , Osteoporotic Fractures/physiopathology , Recurrence , Spinal Fractures/etiology , Spinal Fractures/physiopathology , Spinal Fractures/prevention & control
6.
Osteoporos Int ; 28(10): 2967-2973, 2017 10.
Article in English | MEDLINE | ID: mdl-28748386

ABSTRACT

Trabecular bone score (TBS) assesses bone quality in the lumbar spine using dual-energy X-ray absorptiometry (DXA) scans. In postmenopausal women with osteoporosis, denosumab significantly improved TBS independently of bone mineral density (BMD). This practical technique may have a role in managing patients with osteoporosis. INTRODUCTION: TBS, a gray-level texture index determined from lumbar spine DXA scans, correlates with bone microarchitecture and enhances assessment of vertebral fracture risk independently of BMD. In the FREEDOM study, denosumab increased BMD and reduced new vertebral fractures in postmenopausal women with osteoporosis. This retrospective analysis explored the effect of denosumab on TBS and the association between TBS and BMD in FREEDOM. METHODS: Postmenopausal women with lumbar spine or total hip BMD T-score <-2.5 and -4.0 or higher at both sites received placebo or denosumab 60 mg subcutaneously every 6 months. TBS indices were determined from DXA scans at baseline and months 12, 24, and 36 in a subset of 285 women (128 placebo, 157 denosumab) who had TBS values at baseline and ≥1 postbaseline visit. RESULTS: Baseline characteristics were comparable between treatment groups; mean (SD) lumbar spine BMD T-score was -2.79 (0.64), and mean (standard deviation [SD]) TBS was 1.200 (0.101) overall. In the placebo group, BMD and TBS increased by ≤0.2% or decreased from baseline at each visit. In the denosumab group, progressive increases from baseline at 12, 24, and 36 months were observed for BMD (5.7, 7.8, and 9.8%) and TBS (1.4, 1.9, and 2.4%). Percentage changes in TBS were statistically significant compared with baseline (p < 0.001) and placebo (p ≤ 0.014). TBS was largely unrelated to BMD, regardless of treatment, either at baseline or for annual changes from baseline (all r 2 ≤ 0.06). CONCLUSIONS: In postmenopausal women with osteoporosis, denosumab significantly improved TBS independently of BMD.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Cancellous Bone/drug effects , Denosumab/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Absorptiometry, Photon/methods , Aged , Bone Density Conservation Agents/pharmacology , Cancellous Bone/physiopathology , Denosumab/pharmacology , Double-Blind Method , Female , Humans , Lumbar Vertebrae/drug effects , Lumbar Vertebrae/physiopathology , Middle Aged , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/physiopathology , Osteoporotic Fractures/prevention & control , Retrospective Studies , Spinal Fractures/physiopathology , Spinal Fractures/prevention & control
7.
Osteoporos Int ; 28(5): 1745-1752, 2017 05.
Article in English | MEDLINE | ID: mdl-28204953

ABSTRACT

No clinically important pharmacokinetic interference of alendronate occurred between a new effervescent formulation of alendronate and levothyroxine when coadministered. The combination does not materially affect levothyroxine absorption. INTRODUCTION: Concurrent treatment of osteoporosis with alendronate (Aln) and hypothyroidism with levothyroxine (LT4) may be problematic because both drugs are to be taken separately after fasting overnight. The primary objective was to assess pharmacokinetic interactions between a new effervescent formulation of Aln (Aln-NEF) and LT4. METHODS: A randomized, open-label, 3-way crossover study was conducted in 30 healthy adults (15 women). Subjects were dosed 3 times, separated by 35 days, after overnight fasts, with Aln-NEF alone (70 mg), LT4 alone (600 µg), or Aln-NEF and LT4 concurrently. Samples were analyzed for plasma Aln and serum LT4. Pharmacokinetic drug-drug interaction was assessed using 90% confidence intervals (CIs) for the test/reference ratio of the geometric means for area under the concentration-time curve from time zero to last measureable time point (AUC0-t ) and maximum concentration (C max). Results were compared to the default no-effect boundaries of 80 to 125% for the ratio Aln-NEF and LT4 concurrently/Aln-NEF alone and the ratio Aln-NEF and LT4 concurrently/LT4 alone. RESULTS: Geometric mean ratios (Aln-NEF with LT4/Aln-NEF alone) were 0.927 (90% CI 0.795-1.081) for AUC0-8 and 0.912 (90% CI 0.773-1.077) for C max, demonstrating LT4 does not appreciably affect the pharmacokinetics of Aln. Geometric mean ratios (LT4 with Aln-NEF/LT4 alone) were 1.049 (90% CI 0.983-1.119) for AUC0-48 and 1.075 (90% CI 1.006-1.148) for C max, demonstrating LT4 is bioequivalent between the 2 treatments. Coadministration of Aln-NEF and LT4 was well tolerated. CONCLUSIONS: There was no clinically important pharmacokinetic interference between the Aln-NEF formulation and LT4. Aln-NEF does not materially affect LT4 absorption.


Subject(s)
Alendronate/blood , Bone Density Conservation Agents/blood , Thyroxine/blood , Administration, Oral , Adolescent , Adult , Alendronate/administration & dosage , Alendronate/adverse effects , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/adverse effects , Cross-Over Studies , Drug Administration Schedule , Drug Combinations , Drug Compounding , Drug Interactions , Female , Healthy Volunteers , Humans , Male , Middle Aged , Therapeutic Equivalency , Thyroxine/administration & dosage , Thyroxine/adverse effects , Young Adult
8.
J Clin Endocrinol Metab ; 101(8): 3163-70, 2016 08.
Article in English | MEDLINE | ID: mdl-27270237

ABSTRACT

CONTEXT: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. OBJECTIVE: The objective of the study was to compare the effect of transitioning from oral bisphosphonates to denosumab or ZOL on bone mineral density (BMD) and bone turnover. DESIGN AND SETTING: This was an international, multicenter, randomized, double-blind trial. PARTICIPANTS: A total of 643 postmenopausal women with osteoporosis previously treated with oral bisphosphonates participated in the study. INTERVENTIONS: Subjects were randomized 1:1 to sc denosumab 60 mg every 6 months plus iv placebo once or ZOL 5 mg iv once plus sc placebo every 6 months for 12 months. MAIN OUTCOME MEASURES: Changes in BMD and bone turnover markers were measured. RESULTS: BMD change from baseline at month 12 was significantly greater with denosumab compared with ZOL at the lumbar spine (primary end point; 3.2% vs 1.1%; P < .0001), total hip (1.9% vs 0.6%; P < .0001), femoral neck (1.2% vs -0.1%; P < .0001), and one-third radius (0.6% vs 0.0%; P < .05). The median decrease from baseline was greater with denosumab than ZOL for serum C-telopeptide of type 1 collagen at all time points after day 10 and for serum procollagen type 1 N-terminal propeptide at month 1 and at all time points after month 3 (all P < .05). Median percentage changes from baseline in serum intact PTH were significantly greater at months 3 and 9 with denosumab compared with ZOL (all P < .05). Adverse events were similar between groups. Three events consistent with the definition of atypical femoral fracture were observed (two denosumab and one ZOL). CONCLUSIONS: In postmenopausal women with osteoporosis previously treated with oral bisphosphonates, denosumab was associated with greater BMD increases at all measured skeletal sites and greater inhibition of bone remodeling compared with ZOL.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Denosumab/therapeutic use , Diphosphonates/administration & dosage , Imidazoles/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Administration, Oral , Aged , Bone Density/drug effects , Diphosphonates/therapeutic use , Double-Blind Method , Drug Substitution , Female , Humans , Middle Aged , Zoledronic Acid
10.
Osteoporos Int ; 26(12): 2773-83, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26202488

ABSTRACT

UNLABELLED: The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years was associated with persistent reduction of bone turnover, continued increases in bone mineral density, low fracture incidence, and a favorable benefit/risk profile. INTRODUCTION: This study aims to report the results through year 5 of the FREEDOM Extension study, representing up to 8 years of continued denosumab treatment in postmenopausal women with osteoporosis. METHODS: Women who completed the 3-year FREEDOM study were eligible to enter the 7-year open-label FREEDOM Extension in which all participants are scheduled to receive denosumab, since placebo assignment was discontinued for ethical reasons. A total of 4550 women enrolled in the Extension (2343 long-term; 2207 cross-over). In this analysis, women in the long-term and cross-over groups received denosumab for up to 8 and 5 years, respectively. RESULTS: Throughout the Extension, sustained reduction of bone turnover markers (BTMs) was observed in both groups. In the long-term group, mean bone mineral density (BMD) continued to increase significantly at each time point measured, for cumulative 8-year gains of 18.4 and 8.3 % at the lumbar spine and total hip, respectively. In the cross-over group, mean BMD increased significantly from the Extension baseline for 5-year cumulative gains of 13.1 and 6.2 % at the lumbar spine and total hip, respectively. The yearly incidence of new vertebral and nonvertebral fractures remained low in both groups. The incidence of adverse and serious adverse events did not increase over time. Through Extension year 5, eight events of osteonecrosis of the jaw and two events of atypical femoral fracture were confirmed. CONCLUSIONS: Denosumab treatment for up to 8 years was associated with persistent reductions of BTMs, continued BMD gains, low fracture incidence, and a consistent safety profile.


Subject(s)
Bone Density Conservation Agents/administration & dosage , Denosumab/administration & dosage , Osteoporosis, Postmenopausal/drug therapy , Aged , Aged, 80 and over , Bone Density/drug effects , Bone Density Conservation Agents/adverse effects , Bone Density Conservation Agents/therapeutic use , Bone Remodeling/drug effects , Cross-Over Studies , Denosumab/adverse effects , Denosumab/therapeutic use , Drug Administration Schedule , Female , Humans , Middle Aged , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/physiopathology , Osteoporotic Fractures/prevention & control , Spinal Fractures/physiopathology , Spinal Fractures/prevention & control
11.
Osteoporos Int ; 26(2): 699-712, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25432773

ABSTRACT

SUMMARY: Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and increases bone mineral density, with only a transient decrease in bone formation. We describe the background, design and participant characteristics for the phase 3 registration trial. INTRODUCTION: Odanacatib (ODN) is a selective cathepsin K inhibitor being evaluated for the treatment of osteoporosis. In a phase 2 trial, ODN 50 mg once weekly reduced bone resorption while preserving bone formation and progressively increased BMD over 5 years. We describe the phase III Long-Term ODN Fracture Trial (LOFT), an event-driven, randomized, blinded placebo-controlled trial, with preplanned interim analyses to permit early termination if significant fracture risk reduction was demonstrated. An extension was planned, with participants remaining on their randomized treatment for up to 5 years, then transitioning to open-label ODN. METHODS: The three primary outcomes were radiologically determined vertebral, hip, and clinical non-vertebral fractures. Secondary end points included clinical vertebral fractures, BMD, bone turnover markers, and safety and tolerability, including bone histology. Participants were women, 65 years or older, with a BMD T-score≤-2.5 at the total hip (TH) or femoral neck (FN) or with a prior radiographic vertebral fracture and a T-score≤-1.5 at the TH or FN. They were randomized to ODN or placebo tablets. All received weekly vitamin D3 (5600 international units (IU)) and daily calcium supplements as needed to ensure a daily intake of approximately 1200 mg. RESULTS: Altogether, 16,713 participants were randomized at 387 centers. After a planned interim analysis, an independent data monitoring committee recommended that the study be stopped early due to robust efficacy and a favorable benefit/risk profile. Following the base study closeout, 8256 participants entered the study extension. CONCLUSIONS: This report details the background and study design of this fracture end point trial and describes the baseline characteristics of its participants.


Subject(s)
Biphenyl Compounds/therapeutic use , Bone Density Conservation Agents/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Osteoporotic Fractures/prevention & control , Aged , Biphenyl Compounds/adverse effects , Biphenyl Compounds/pharmacology , Bone Density/drug effects , Bone Density Conservation Agents/adverse effects , Bone Density Conservation Agents/pharmacology , Cathepsin K/antagonists & inhibitors , Double-Blind Method , Female , Femur Neck/physiopathology , Hip Joint/physiopathology , Humans , Osteoporosis, Postmenopausal/complications , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/etiology , Osteoporotic Fractures/physiopathology , Patient Selection , Research Design , Treatment Outcome
12.
J. clin. endocrinol. metab ; 99(12)Dec. 2014. tab
Article in English | BIGG - GRADE guidelines | ID: biblio-965831

ABSTRACT

OBJECTIVE: The aim of this guideline was to formulate practice guidelines for the diagnosis and treatment of Paget's disease of the bone. PARTICIPANTS: The guideline was developed by an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence. CONCLUSIONS: We recommend that plain radiographs be obtained of the pertinent regions of the skeleton in patients with suspected Paget's disease. If the diagnosis is confirmed, we suggest that a radionucleotide bone scan be done to determine the extent of the disease. After diagnosis of Paget's disease, we recommend measurement of serum total alkaline phosphatase or, when warranted, a more specific marker of bone formation or bone resorption to assess the response to treatment or evolution of the disease in untreated patients. We suggest treatment with a bisphosphonate for most patients with active Paget's disease who are at risk for future complications. We suggest a single 5-mg dose of iv zoledronate as the treatment of choice in patients who have no contraindication. In patients with monostotic disease who have a normal serum total alkaline phosphatase, we suggest that a specific marker of bone formation and bone resorption be measured, although these may still be normal. Serial radionuclide bone scans may determine the response to treatment if the markers are normal. We suggest that bisphosphonate treatment may be effective in preventing or slowing the progress of hearing loss and osteoarthritis in joints adjacent to Paget's disease and may reverse paraplegia associated with spinal Paget's disease. We suggest treatment with a bisphosphonate before surgery on pagetic bone.(AU)


Subject(s)
Humans , Osteitis Deformans/drug therapy , Osteitis Deformans/diagnostic imaging , Diphosphonates/therapeutic use , Alkaline Phosphatase/therapeutic use , Biomarkers
13.
Osteoporos Int ; 25(11): 2649-56, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25027109

ABSTRACT

UNLABELLED: The effect of an investigational oral calcitonin tablet upon bone mineral density (BMD) of the spine was investigated in postmenopausal women with low bone mass and at increased risk of fracture. Compared to placebo, calcitonin tablets increased lumbar spine BMD. This agent may provide an additional choice for patients. INTRODUCTION: An investigational oral salmon calcitonin preparation was previously shown to increase lumbar spine BMD in postmenopausal women with osteoporosis. Our objective was to evaluate the use of this agent in postmenopausal women with low bone mass and at increased fracture risk but not meeting BMD criteria for osteoporosis. METHODS: Treatment-naïve women were randomized to receive oral recombinant salmon calcitonin tablets or placebo once daily for 1 year. Dual-energy X-ray absorptiometry was performed at baseline and at study weeks 28 and 54. CTx-1, a bone resorption marker, was obtained at the same time points. Subjects returned periodically for tolerability assessment and adverse event (AE) recording. RESULTS: One hundred twenty-nine women in the USA were randomized, 86 to calcitonin and 43 to placebo. Calcitonin recipients experienced a significant increase from baseline in lumbar spine BMD; the difference compared with placebo was significant. Dosing at bedtime or with dinner was equally effective. CTx-1 was suppressed in calcitonin recipients but not in placebo subjects. Gastrointestinal AEs were common, but the overall safety profile was comparable between groups. CONCLUSIONS: Oral calcitonin may provide a useful therapeutic alternative for some women with low bone mass.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Calcitonin/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Osteoporotic Fractures/prevention & control , Absorptiometry, Photon/methods , Administration, Oral , Aged , Biomarkers/blood , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/adverse effects , Calcitonin/administration & dosage , Calcitonin/adverse effects , Collagen Type I/blood , Double-Blind Method , Female , Femur Neck/physiopathology , Hip Joint/physiopathology , Humans , Lumbar Vertebrae/physiopathology , Middle Aged , Osteoporosis, Postmenopausal/complications , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/etiology , Peptides/blood , Single-Blind Method , Treatment Outcome
14.
Osteoporos Int ; 25(7): 1953-61, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24676847

ABSTRACT

UNLABELLED: Managing osteoporotic patients suboptimally adherent to bisphosphonates (BPs) is difficult. Such patients who remained at higher risk for fracture (≥1 risk factor) were transitioned to denosumab or a monthly oral BP. Denosumab-treated subjects had significantly greater increases in bone mineral density and decreases in bone turnover in this 12-month study. INTRODUCTION: A clinical need exists to manage patients who are suboptimally adherent to oral BPs and remain at higher risk for fracture. Here, we compare the effects on bone mineral density (BMD) and bone turnover of transitioning such patients to denosumab or monthly oral BP (ibandronate or risedronate). METHODS: In two previous multicenter, open-label studies, postmenopausal women ≥55 years previously treated with, though suboptimally adherent to, a daily or weekly BP were randomized to denosumab 60 mg subcutaneously every 6 months (N = 852) or oral BP 150 mg monthly (N = 851) for 12 months. In this combined post-hoc analysis, a subset of higher risk subjects was identified, and the percentage changes from baseline in BMD and serum C-telopeptide of type I collagen (sCTX-1) were assessed. RESULTS: In the overall population, denosumab was associated with greater gains in BMD at 12 months than monthly oral BP at the total hip, femoral neck, and lumbar spine (p < 0.0001 for all). In higher risk subjects, denosumab led to greater gains in BMD than oral BPs at the total hip (2.2 vs 0.8 %), femoral neck (1.8 vs 0.3 %), and lumbar spine (3.7 vs 1.4 %) (p < 0.0001 for all). Denosumab also led to greater decreases in sCTX-1 in the overall population and higher risk subjects at months 1 and 6 (p < 0.0001 for both). Adverse events and serious adverse events were generally similar between treatment groups. CONCLUSIONS: Transitioning to denosumab was well tolerated and more effective in increasing BMD and reducing bone turnover than cycling to a monthly oral BP treatment in subjects who remained at higher fracture risk despite suboptimal BP treatment.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Osteoporosis, Postmenopausal/drug therapy , Osteoporotic Fractures/prevention & control , Administration, Oral , Aged , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/pharmacology , Biomarkers/blood , Bone Density Conservation Agents/adverse effects , Bone Density Conservation Agents/pharmacology , Bone Remodeling/drug effects , Collagen Type I/blood , Denosumab , Diphosphonates/adverse effects , Diphosphonates/pharmacology , Diphosphonates/therapeutic use , Drug Administration Schedule , Etidronic Acid/adverse effects , Etidronic Acid/analogs & derivatives , Etidronic Acid/pharmacology , Etidronic Acid/therapeutic use , Female , Femur Neck/physiopathology , Hip Joint/physiopathology , Humans , Ibandronic Acid , Injections, Subcutaneous , Lumbar Vertebrae/physiopathology , Medication Adherence , Middle Aged , Osteoporosis, Postmenopausal/complications , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/etiology , Osteoporotic Fractures/physiopathology , Peptides/blood , Randomized Controlled Trials as Topic , Risedronic Acid , Risk Factors
15.
Osteoporos Int ; 24(4): 1503-11, 2013 Apr.
Article in English | MEDLINE | ID: mdl-22930240

ABSTRACT

UNLABELLED: The purpose of this study is to examine the effect of PTH(1-84) treatment over 24 months followed by 12 months discontinuation on BMD, bone turnover markers, fractures and the impact of adherence on efficacy. INTRODUCTION: There is limited information about the effect of PTH(1-84) after 18 months and limited data about the impact of compliance on response to anabolic therapy. METHODS: Seven hundred and eighty-one subjects who received active PTH(1-84) in the Treatment of Osteoporosis with Parathyroid hormone trial for approximately 18 months were entered into a 6-month open-label extension. Thereafter, they were followed for 12 additional months after discontinuation of treatment. Endpoints examined included changes in BMD and biochemical markers. RESULTS: PTH(1-84) treatment over 24 months increased BMD at the lumbar spine by 6.8% above baseline (p<0.05).The total corresponding BMD increases at the hip and femoral neck were 1.1 and 2.2% above baseline. Larger increases in spine BMD were observed in participants with ≥80% adherence to daily injections of PTH(1-84) (8.3% in adherent vs 4.9% in poorly adherent patients). Total hip BMD gains were 1.7% in adherent vs 0.6% in poorly adherent participants. Markers of bone turnover (BSAP and NTx) peaked 6 months after starting PTH(1-84) treatment and declined slowly but remained above baseline at 24 months. After discontinuation of PTH(1-84) treatment (at 24 months), bone turnover markers returned to near baseline levels by 30 months. The adherent group sustained significantly fewer fractures than the poorly adherent group. CONCLUSIONS: PTH(1-84) treatment over 24 months results in continued increases in lumbar spine BMD. Adherence to treatment with PTH(1-84) for up to 24 months is also associated with greater efficacy.


Subject(s)
Bone Density Conservation Agents/administration & dosage , Bone Density/drug effects , Medication Adherence/statistics & numerical data , Osteoporosis, Postmenopausal/drug therapy , Parathyroid Hormone/administration & dosage , Aged, 80 and over , Biomarkers/blood , Bone Density Conservation Agents/adverse effects , Bone Density Conservation Agents/therapeutic use , Bone Remodeling/drug effects , Double-Blind Method , Female , Femur Neck/physiopathology , Follow-Up Studies , Hip Joint/physiopathology , Humans , Lumbar Vertebrae/physiopathology , Middle Aged , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/prevention & control , Parathyroid Hormone/adverse effects , Parathyroid Hormone/therapeutic use , Radius/physiopathology , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Spinal Fractures/prevention & control , Treatment Outcome
16.
Mucosal Immunol ; 6(3): 535-46, 2013 May.
Article in English | MEDLINE | ID: mdl-23032791

ABSTRACT

The B subunit of E. coli heat-labile enterotoxin (EtxB) protects against the development of T helper type 1 (Th1)-mediated autoimmune pathologies in mice. Protection was transferable with splenic CD4(+) T cells and was less effective following CD25 depletion; implying a T regulatory cell (Treg)-mediated process. We hypothesized that if this were the case, then EtxB would also control a Th2-mediated disorder. We tested the effect of EtxB treatment on asthma development in ovalbumin (OVA)-sensitized mice. EtxB treatment diminished eosinophilia in bronchoalveolar lavage samples, reduced OVA-specific immunoglobulin E and interleukin 4 production locally and systemically, and reduced airway hyper-reactivity. EtxB induced a dose-dependent increase in Foxp3(+)CD4(+) T cells, and adoptive transfer of splenic CD4(+) T cells partially suppressed lung pathology. Importantly, EtxB treatment increased OVA-specific CD4(+)Foxp3(+) T cells in the lung and systemically. These data demonstrate that EtxB modulates the differentiation of allergen-specific T cells causing inducible Treg induction and preventing disease.


Subject(s)
Asthma/prevention & control , Autoimmune Diseases/prevention & control , Bacterial Toxins/administration & dosage , Enterotoxins/administration & dosage , Escherichia coli Proteins/administration & dosage , T-Lymphocytes, Regulatory/immunology , Th2 Cells/immunology , Animals , Asthma/immunology , CD4 Antigens/metabolism , Cells, Cultured , Eosinophils/immunology , Female , Immunity, Humoral , Immunoglobulin E/blood , Immunosuppression Therapy , Interleukin-4/metabolism , Lymphocyte Activation/drug effects , Lymphocyte Depletion , Mice , Mice, Inbred BALB C , Ovalbumin/immunology
17.
Anaesthesist ; 61(3): 224-6, 228, 2012 Mar.
Article in German | MEDLINE | ID: mdl-22430552

ABSTRACT

A case report of severe rhabdomyolysis in a 33-year-old motorcyclist after multiple trauma is described. The injuries included severe thoracic and abdominal trauma as well as injuries to the extremities and spinal column. During the first 3 days of treatment a forced volume therapy was performed because of increased levels of creatine kinase during which the patients condition stabilized both hemodynamically and respiratorily. On day 10 the patient developed a rise in temperature to 42°C with no evidence of a re-infection and the creatine kinase levels rose to 109,830 U/l. A continuous hemofiltration was started because of acute renal failure. The creatine kinase levels declined significantly and renal function also returned to normal with adequate diuresis up to day 20. After intensive questioning of the relatives a history of long-term use of anabolic steroids, clenbuterol as well as the intake of testosterone enanthate was conceded. Cocaine and amphetamines were also taken regularly by the patient.


Subject(s)
Hemofiltration , Multiple Trauma/complications , Multiple Trauma/therapy , Rhabdomyolysis/etiology , Rhabdomyolysis/therapy , Acute Kidney Injury/etiology , Acute Kidney Injury/therapy , Adrenergic beta-Agonists/adverse effects , Adult , Amphetamine-Related Disorders/complications , Anabolic Agents/adverse effects , Body Temperature/physiology , Clenbuterol/adverse effects , Cocaine-Related Disorders/complications , Creatine Kinase/blood , Fever/etiology , Fluid Therapy , Humans , Male , Rhabdomyolysis/diagnosis , Substance-Related Disorders/complications , Testosterone/adverse effects , Testosterone/analogs & derivatives
18.
Osteoporos Int ; 23(1): 233-45, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21369791

ABSTRACT

UNLABELLED: In this meta-analysis of all Merck-conducted, placebo-controlled clinical trials of alendronate, the occurrence of AF was uncommon, with most studies reporting two or fewer events. Across all studies, no clear association between overall bisphosphonate exposure and the rate of serious or non-serious AF was observed. INTRODUCTION: To explore the incidence of atrial fibrillation (AF) and other cardiovascular endpoints in clinical trials of alendronate. METHODS: All double-blind, placebo-controlled studies of alendronate 5, 10, or 20 mg daily, 35 mg once-weekly, 35 mg twice-weekly, and 70 mg once-weekly of at least 3 months duration conducted by Merck were included in this meta-analysis. The primary method of analysis was exact Poisson regression. Estimated relative risk (RR) of alendronate versus placebo and the associated 95% confidence interval was derived from a model that included number of episodes with factors for treatment group and study and an offset parameter for number of person-years on study. RESULTS: Of 41 studies considered, 32 met all criteria for inclusion in the analysis (participants-9,518 alendronate, 7,773 placebo). Estimated RR for all AF events was 1.16 (95% CI = 0.87, 1.55; p = 0.33). Most trials had two or fewer AF events. The RR of AF classified as a serious adverse event was 1.25 (95% CI = 0.82, 1.93; p = 0.33), but became 0.97 (95% CI = 0.51, 1.85) when the clinical fracture cohort of the Fracture Intervention Trial was excluded, indicating that results were driven by events in that study. Estimated RRs for other cardiovascular endpoints were less than 1. CONCLUSIONS: The incidence of atrial fibrillation was low in Merck clinical trials of alendronate and was not significantly increased in any single trial nor in the meta-analysis. Based on this analysis, alendronate use does not appear to be associated with an increased risk of atrial fibrillation.


Subject(s)
Alendronate/adverse effects , Atrial Fibrillation/chemically induced , Bone Density Conservation Agents/adverse effects , Alendronate/administration & dosage , Atrial Fibrillation/epidemiology , Bone Density Conservation Agents/administration & dosage , Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/epidemiology , Dose-Response Relationship, Drug , Humans , Incidence , Osteoporosis/drug therapy , Randomized Controlled Trials as Topic
19.
Ger Med Sci ; 8: Doc14, 2010 Jun 28.
Article in English, German | MEDLINE | ID: mdl-20628653

ABSTRACT

Practice guidelines are systematically developed statements and recommendations that assist the physicians and patients in making decisions about appropriate health care measures for specific clinical circumstances taking into account specific national health care structures. The 1(st) revision of the S-2k guideline of the German Sepsis Society in collaboration with 17 German medical scientific societies and one self-help group provides state-of-the-art information (results of controlled clinical trials and expert knowledge) on the effective and appropriate medical care (prevention, diagnosis, therapy and follow-up care) of critically ill patients with severe sepsis or septic shock. The guideline had been developed according to the "German Instrument for Methodological Guideline Appraisal" of the Association of the Scientific Medical Societies (AWMF). In view of the inevitable advancements in scientific knowledge and technical expertise, revisions, updates and amendments must be periodically initiated. The guideline recommendations may not be applied under all circumstances. It rests with the clinician to decide whether a certain recommendation should be adopted or not, taking into consideration the unique set of clinical facts presented in connection with each individual patient as well as the available resources.


Subject(s)
Continuity of Patient Care/standards , Critical Care/standards , Emergency Medical Services/standards , Patient Care Team/standards , Sepsis , Follow-Up Studies , Germany , Humans , Sepsis/diagnosis , Sepsis/prevention & control , Sepsis/therapy
20.
J Pediatr Adolesc Gynecol ; 23(4): 209-14, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20471875

ABSTRACT

STUDY OBJECTIVE: To examine vitamin D and parathormone (PTH) levels in adolescents who experienced substantial bone mineral density (BMD) loss during depot medroxyprogesterone acetate (DMPA) use. DESIGN: A non-randomized, multi-center study, during which DMPA was administered every 12 weeks and evaluation of lumbar spine and hip BMD by dual-energy X-ray absorptiometry (DXA) was conducted every 6 months. A blood sample for vitamin D and PTH measurements was obtained from adolescents who experienced >5% BMD loss. Vitamin D deficiency was defined as 25-hydroxyvitamin D (25OHD) level of <20 ng/mL, insufficiency as 25OHD level of 20-30 ng/mL, and sufficiency as 25OHD level of >30 ng/mL. RESULTS: Evaluation of vitamin D and PTH was carried out in 15 participants who experienced BMD loss of > or = 5% during DMPA use. At initiation of DMPA, participants had mean (+SE) age 17+1 years, gynecologic age 61+4 months, and body mass index 24+1.5 kg/m2. Racial/ethnic distribution was: Caucasian--7 girls, Hispanic--4 girls, African-American--3 girls, and other--1 girl. Six participants had BMD loss of >5% after 2 DMPA injections, five after 3 injections, one after 5 injections, one after 8 injections, one after 10 injections, and one after 13 injections. Only one girl (7%) had sufficient vitamin D. The other participants had vitamin D insufficiency (50%) or deficiency (43%). Participants' mean (+SE) PTH was 22+4 pg/mL (reference range 7-53 pg/mL), and mean (+SE) 1,25-dihydroxyvitamin D was 56+5 pg/mL (reference range 22-67 pg/mL). CONCLUSIONS: Inadequate vitamin D status was evident among the majority of female adolescents who experienced a substantial BMD loss while using DMPA.


Subject(s)
Bone Density/drug effects , Bone Diseases, Metabolic/etiology , Contraceptive Agents, Female/adverse effects , Medroxyprogesterone Acetate/adverse effects , Vitamin D Deficiency/complications , Adolescent , Drug Implants , Female , Humans , Parathyroid Hormone/blood , Pilot Projects , Vitamin D/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...